

CORRIGENDUM: Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies

Patricia A. Deverka MD, MS, Sheri D. Schully PhD, Naoko Ishibe ScD, Josh J. Carlson PhD, Andrew Freedman PhD, Katrina A.B. Goddard PhD, Muin J. Khoury MD, PhD and Scott D. Ramsey MD, PhD

Genet Med 2012;14:656–662; advance online publication, 5 April 2012; doi:[10.1038/gim.2012.3](https://doi.org/10.1038/gim.2012.3)

The data included in the published version of **Figure 1** was incorrect; duplicate data for 2 of the 3 genetic tests (Oncotype DX and epidermal growth factor receptor) was inadvertently presented. The corrected version of the figure is below with the revised data for epidermal growth factor receptor testing.

In the Results section of the Abstract, the second sentence was given as: “Following the discussion, survey results reflected even less confidence for Oncotype DX and epidermal growth factor receptor mutation testing, but not for Lynch syndrome testing.” It should have read: “Following the discussion, survey results reflected less confidence for Oncotype DX, intermediate levels of confidence for epidermal growth factor receptor mutation testing and stable levels of confidence for Lynch syndrome testing.”

The authors regret these errors.




Figure 1 Stakeholder answers (during the meeting) to “At this time, what recommendation would you make regarding: (a) Oncotype DX; (b) Lynch syndrome; (c) EGFR.” EGFR, epidermal growth factor receptor.